McKesson Reports Fiscal 2007 Fourth-Quarter and Full-Year Results

McKesson Corporation (NYSE:MCK) today reported that revenues for the fourth quarter ended March 31, 2007, were $24.2 billion compared to $22.8 billion a year ago. Fourth-quarter earnings per diluted share was 85 cents compared to 70 cents per diluted share a year ago. Fourth-quarter earnings per diluted share from continuing operations excluding adjustments to Securities Litigation reserves was 85 cents compared to 69 cents a year ago. For the full fiscal year, McKesson had revenues of $93.0 billion versus $87.0 billion a year ago, and earnings per diluted share of $2.99 compared to $2.38 a year ago. Earnings per diluted share from continuing operations excluding adjustments to Securities Litigation reserves for the full year was $2.89 compared to $2.46 a year ago. "McKesson’s outstanding earnings growth for the quarter and for the year is the result of great execution across the company,” said John H. Hammergren, chairman and chief executive officer. "We are seeing the benefits of our strategy to deliver products, services and solutions that are helping our customers make healthcare safer, more efficient and higher quality. Our financial performance, operating excellence and strategic capital deployment provide great momentum for Fiscal 2008.” "Pharmaceutical Solutions full-year operating margin rate expanded to 1.53%, an increase of 8 basis points, a strong performance considering we had $95 million in positive anti-trust settlements a year ago compared to $10 million this year. Medical-Surgical Solutions grew revenues 16% while completing a seamless transition out of the acute care business. Provider Technologies revenues grew 24% and operating profit increased 11% even as we continued to make significant investments in product development, sales force expansion and acquisitions to expand our offering and strengthen our positions in emerging markets.” For the year, McKesson had cash flow from operations of $1.5 billion. The company continues to execute a balanced capital deployment strategy designed to create additional shareholder value. During Fiscal 2007, McKesson made $1.9 billion of acquisitions, including the acquisition of Per-Se Technologies on January 26 for $1.8 billion, repurchased $1 billion of its shares, paid $72 million in dividends and invested $306 million in property, plant, equipment and capitalized software. During the quarter, McKesson issued $1 billion in debt to finance its purchase of Per-Se. The company ended the year with a cash balance of $2 billion and a gross debt-to-capital ratio of 24%. During the fourth quarter, McKesson repurchased $247 million of stock, completing the previously authorized repurchase program. At its most recent meeting, the Board of Directors authorized an additional $1 billion share repurchase program. Segment Results Pharmaceutical Solutions revenues were up 5% for the fourth quarter and 6% for the year. U.S. Healthcare direct distribution revenues grew 4% for the quarter and 5% for the year despite the mid-May 2006 termination of a customer contract with annual sales of approximately $3.3 billion. Warehouse sales increased 7% in the quarter and 8% for the year. For the quarter and the year, Canadian revenues increased 13%, including a negative 2% currency impact for the quarter and a 5% currency benefit for the year. Pharmaceutical Solutions gross profit of $794 million was up 16% from the fourth quarter a year ago. Full-year gross profit of $2.8 billion was up 11% from a year ago. The increases in gross profit for the quarter and year resulted from an improved mix of higher-margin products and services, stable sell margin to customers and the impact of our agreements with branded pharmaceutical manufacturers. Gross profit in the fourth quarter included a $26 million pre-tax LIFO credit compared to $12 million in the fourth quarter a year ago. For the full year, the pre-tax LIFO credit was $64 million compared to $32 million a year ago. Gross profit in Fiscal 2007 included $10 million in pre-tax gains from anti-trust settlements compared to $95 million for Fiscal 2006. Operating margin rate for the fourth quarter was 1.77% compared to 1.61% a year ago, and was 1.53% for the full year compared to 1.45% a year ago. "Our success at expanding our operating margin comes from our dedication to increasing the higher-margin products and services we provide to our customers, disciplined execution with customer contract renewals and focus on operating expense efficiencies,” said Hammergren. Medical-Surgical Solutions revenues were up 13% in the fourth quarter and 16% for the full year, both of which reflect above-market growth across the business and the acquisition of Sterling Medical in April 2006. Gross profit as a percentage of revenues was 30% for the quarter and 29% for the year. Operating profit in the fourth quarter was $11 million compared to $16 million a year ago, and for the full year was $81 million compared to $83 million a year ago. In Provider Technologies, revenues were up 39% for the quarter and 24% for the full year, reflecting continued strong demand for clinical software and imaging solutions, increased implementations and the impact of Per-Se revenues. Software and software systems revenues increased 7% for the quarter and 16% for the full year. Provider Technologies’ operating profit in the fourth quarter was $51 million, up 6% from the fourth quarter a year ago, and for the full year was $159 million, up 11%. Operating expenses were up 45% for the quarter and 27% for the year due to the impact of Per-Se and other acquisitions, new product development investments, sales force expansion, restructurings and equity-based compensation expense allocated to this segment. Operating margin rate was 8.54% for the quarter and 8.35% for the year. "Over the past year, Provider Technologies solidified its leadership position for comprehensive information solutions in its traditional core hospital customer base,” Hammergren said. "We also moved aggressively with strategic acquisitions to expand our positions in physician office information solutions, consumer-directed healthcare and healthcare connectivity. The integration of those acquisitions into our business is well under way. Demand remains strong, especially for our market-leading medical imaging solutions, and we continue to benefit from an improved pace of implementations to pull revenue from our software backlog.” Fiscal Year 2008 Outlook "Based on the demonstrated value of our product and service offering, our operating progress and strategic investments, McKesson enters Fiscal 2008 well-positioned for growth in both existing and emerging markets for healthcare services and healthcare information technology,” Hammergren continued. "We are the largest pharmaceutical distributor in the United States and Canada, and own 49% of the leading pharmaceutical distributor in Mexico. We are the largest distributor of generics in North America, at a time when the consumption of these drugs is growing due to their great value. We are well-positioned in the attractive alternate site medical-surgical market.” "Software and automation solutions that can improve the efficiency and quality of healthcare have tremendous value for our customers. We continue to see strong demand for our solutions from our large installed base of hospital and payor customers. We have unique offerings for the emerging sectors of the market and are using technology to connect all participants across the healthcare spectrum.” "Based on this positive momentum, for the fiscal year ending March 31, 2008, McKesson expects to earn between $3.15 and $3.30 per diluted share. A strong balance sheet and solid operating cash flow provide resources to further the creation of additional shareholder value,” Hammergren concluded. Key Assumptions for Fiscal Year 2008 Outlook The Fiscal 2008 outlook is based on the key assumptions provided below and is also subject to the Risk Factors provided below in this press release. Beginning with the quarter ending June 30, 2007, McKesson will report its results in two segments: McKesson Distribution Solutions, which includes what was previously reported as Pharmaceutical Solutions and Medical-Surgical Solutions, with the exception of our Payor business, which will now be reported together with Provider Technologies in the second segment, McKesson Technology Solutions. Revenue growth for our Distribution Solutions segment should be at market growth rates, adjusted for our mix of business. Technology Solutions segment revenue growth should be significantly above market revenue growth due to the Per-Se acquisition, demand for healthcare information solutions and continued software implementations. Although our agreements with branded pharmaceutical manufacturers provide a higher level of predictability for compensation, the structures of some agreements use price increases as the determinant of compensation timing and therefore a seasonal pattern of earnings is expected to continue. We assume that price inflation in Fiscal 2008 will be similar to price inflation in Fiscal 2007. Another year of strong growth in sales and profit from generic pharmaceuticals is expected, but whereas there were a number of major generic drug launches in the first two quarters of Fiscal 2007, the current expectation is that the majority of generic drug launches in Fiscal 2008 will occur late in the fiscal year. Our remaining pharmaceutical LIFO reserve of approximately $18 million is expected to be used in 2008. Positive anti-trust settlements are expected to be at approximately the same level in Fiscal 2008 as they were in Fiscal 2007. McKesson’s incremental equity-based compensation expense is expected to be between 6 and 8 cents per diluted share in Fiscal 2008, due to the multi-year ramp-up of expense. This expense will have a more significant impact on the operating profit of the Technology Solutions segment. Our share-based compensation expense is affected by a number of variables, including changes in our stock price, levels of grants, forfeiture rates and the attainment of performance goals. As a result, there could continue to be variability in this expense in the coming fiscal year. The guidance range assumes a tax rate range of 34% to 35%, which may vary from quarter to quarter. Capital expenditures and capitalized software should be between $300 million and $350 million. Cash flow from operations is expected to be in excess of $1 billion. Average shares outstanding used for calculation of diluted earnings per share is expected to be 302 million. The guidance range does not include any potential securities litigation reserve adjustments, acquisitions, divestitures, material restructurings or integration-related actions. Fourth-Quarter and Full-Year Corporate and Financial Highlights The quarter and year included the following additional major highlights: On April 25, the Board of Directors authorized an additional repurchase from time to time of up to $1 billion of the company's shares of common stock in open market or private transactions. Sales growth for McKesson’s proprietary OneStop generics program for retail pharmacy once again exceeded the market growth rate for generic pharmaceuticals, and was up 40% in the quarter and 51% for the year. Since introducing an enhanced Health Mart® program July 1, our franchise count increased from 350 stores to almost 1,300 stores, making Health Mart the largest independent domestic pharmacy franchise network. Health Mart was recently recognized as "Pharmacy Chain of the Year” by Drug Topics magazine. During Fiscal 2007, we renewed longstanding relationships with several of our largest customers, including Wal-Mart, Target and Aetna, and expanded our relationships with CVS and Broadlane. McKesson’s Medical Imaging Group is the recipient of the Frost and Sullivan Market Penetration Leadership Award in the U.S. PACS industry for the second consecutive year. The award citation reads: "The recipient has demonstrated strategic excellence in product innovation, marketing, and sales strategies that have resulted in the largest gain in market share over the past 2 to 3 years.” McKesson remains the leader in medication safety, with the only fully integrated solution spanning information systems, automated drug dispensing and bedside error prevention. McKesson’s Robot-Rx® is installed in 325 hospitals in the United States and Canada, where it dispenses half a billion doses annually, error-free. McKesson’s Horizon Admin-RxTM bedside scanning technology monitors more than 95 million drug administrations annually, preventing more than 325,000 errors weekly. We acquired Practice Partner, a leading provider of integrated software for electronic health records (EHRs), medical billing and appointment scheduling for independent physician practices. The acquisition supports McKesson’s commitment to provide a complete solution – including software, billing and collection services, supplies and connectivity – to physician practices regardless of size, specialty or geographic location. More than 50% of sites are installed and running under McKesson’s contract to install and operate a new payroll and human resources information system for the National Health Service of England and Wales. The fourth-quarter provision for income taxes reflects a reduction in the company’s full-year expected effective tax rate to 33% and favorable adjustments to income tax expense totaling $4 million. Fourth-quarter results included $21 million in pre-tax share-based compensation expense associated with the implementation of FAS 123R. For Fiscal 2007, this pre-tax expense totaled $60 million, or approximately 13 cents per diluted share. Results from discontinued operations in Fiscal 2007 totaled an after-tax loss of $55 million, or 18 cents per diluted share, primarily associated with the September 2006 sale of our acute care medical-surgical business. Risk Factors Except for historical information contained in this press release, matters discussed may constitute "forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as "believes,” "expects,” "anticipates,” "may,” "should,” "seeks,” "approximately,” "intends,” "plans,” "estimates” or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements. It is not possible to predict or identify all such risks and uncertainties; however, the most significant of these risks and uncertainties are described in the company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: adverse resolution of pending securities litigation regarding the 1999 restatement of our historical financial statements; the changing U.S. healthcare environment, including changes in government regulations and the impact of potential future mandated benefits; competition; changes in private and governmental reimbursement or in the delivery systems for healthcare products and services; governmental and manufacturers’ efforts to regulate or control the pharmaceutical supply chain; changes in government regulations relating to patient confidentiality standards; changes in pharmaceutical and medical-surgical manufacturers’ pricing, selling, inventory, distribution or supply policies or practices; changes in the availability or pricing of branded and generic drugs; changes in customer mix; substantial defaults in payment or a material reduction in purchases by large customers; challenges in integrating and implementing the company’s internally used or externally sold software and software systems, or the slowing or deferral of demand or extension of the sales cycle for external software products; continued access to third-party licenses for software and the patent positions of the company’s proprietary software; the company’s ability to meet performance requirements in its disease management programs; the adequacy of insurance to cover liability or loss claims; changes in circumstances that could impair our goodwill or intangible assets; new or revised tax legislation; foreign currency fluctuations or disruptions to foreign operations; the company’s ability to successfully identify, consummate and integrate strategic acquisitions; changes in generally accepted accounting principles (GAAP); and general economic conditions. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The company assumes no obligation to update or revise any such statements, whether as a result of new information or otherwise. A Webcast of the company’s regular conference call to review financial results with the financial community is available through McKesson’s website, www.mckesson.com, live at 5 PM ET today and on replay afterwards. Shareholders are encouraged to review SEC filings and more information about McKesson, which are located on the company’s website. About McKesson McKesson Corporation (NYSE:MCK) is a Fortune 18 healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes and improving the quality and safety of patient care. Over the course of its 174-year history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. For more information, visit us at www.mckesson.com. Schedule I McKESSON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in millions except per share amounts)   Quarter Ended March 31, Year Ended March 31, FY07 FY06 Chg. FY07 FY06 Chg.   Revenues $ 24,165  $ 22,790  6  % $ 92,977  $ 86,983  7  %   Cost of sales   22,914    21,751  5    88,645    83,206  7    Gross profit 1,251  1,039  20  4,332  3,777  15    Operating expenses 883  709  25  3,074  2,606  18  Securities Litigation charge (credit), net   -    (8) -    (6)   45  -  Total operating expenses   883    701  26    3,068    2,651  16    Operating income 368  338  9  1,264  1,126  12    Interest expense (31) (25) 24  (99) (94) 5  Other income, net   26    42  (38)   132    139  (5)   Income from continuing operations before income taxes 363  355  2  1,297  1,171  11    Income taxes (1)   (106)   (132) (20)   (329)   (426) (23)   Income from continuing operations 257  223  15  968  745  30    Discontinued operations, net (2)   -    (3) -    (55)   6  -    Net income $ 257  $ 220  17  $ 913  $ 751  22    Earnings per common share (3) Diluted (4) (5) Continuing operations $ 0.85  $ 0.71  20  % $ 3.17  $ 2.36  34  % Discontinued operations   -    (0.01) -    (0.18)   0.02  -  Total $ 0.85  $ 0.70  21  $ 2.99  $ 2.38  26  Basic Continuing operations $ 0.87  $ 0.73  19  % $ 3.25  $ 2.44  33  % Discontinued operations   -    (0.01) -    (0.19)   0.02  -  Total $ 0.87  $ 0.72  21  $ 3.06  $ 2.46  24    Shares on which earnings per common share were based Diluted 304  314  (3) % 305  316  (3) % Basic 296  305  (3) 298  306  (3)   (1) Income tax expense for the year ended March 31, 2007 includes an $83 million credit to reverse previously recorded Securities Litigation tax reserves.   (2) In the second quarter of 2007, we sold our Acute Care business, which was previously included in our Medical-Surgical Solutions segment, and a small Pharmaceutical Solutions' segment business. Financial results for these businesses have been presented as discontinued operations. Results of our discontinued operations for the year ended March 31, 2007 include the write-off of $79 million of goodwill allocated to the sale of the Acute Care business, none of which is tax deductible.   (3) Certain computations may reflect rounding adjustments.   (4) For the year ended March 31, 2006, interest expense, net of related income taxes, of $1 million has been added to net income for purposes of calculating diluted earnings per share. This adjustment reflects the impact of the Company's potentially dilutive obligations.   (5) Diluted earnings per share from continuing operations, excluding the impact of our Securities Litigation, are as follows (a):   Quarter Ended March 31, Year Ended March 31, FY07 FY06 Chg. FY07 FY06 Chg. Income from continuing operations - as reported $ 257  $ 223  15  % $ 968  $ 745  30  %   Exclude:   Securities Litigation charge (credit), net -  (8) -  (6) 45  -   Income taxes on charge (credit), net -  3  -  2  (15) -   Income tax reserve reversals   -    -  -    (83)   -  -    -    (5) -    (87)   30  -  Income from continuing operations, excluding the Securities Litigation charge (credit), net $ 257  $ 218  18  $ 881  $ 775  14    Diluted earnings per common share from continuing operations, excluding the Securities Litigation charge (credit), net (4) $ 0.85  $ 0.69  23  % $ 2.89  $ 2.46  17  %   (a) These pro forma amounts are non-GAAP financial measures. The Company uses these measures internally and considers these results to be useful to investors as they provide relevant benchmarks of core operating performance. Schedule II McKESSON CORPORATION CONDENSED CONSOLIDATED INCOME INFORMATION BY BUSINESS SEGMENT (unaudited) (in millions)   Quarter Ended March 31, Year Ended March 31, FY07 FY06 Chg. FY07 FY06 Chg. REVENUES Pharmaceutical Solutions U.S. Healthcare direct distribution & services $ 14,245  $ 13,763  4  % $ 54,461  $ 52,032  5  % U.S. Healthcare sales to customers' warehouses   7,142    6,663  7    27,555    25,462  8  Subtotal 21,387  20,426  5  82,016  77,494  6  Canada distribution & services   1,606    1,425  13    6,692    5,910  13  Total Pharmaceutical Solutions   22,993    21,851  5    88,708    83,404  6    Medical-Surgical Solutions   575    508  13    2,364    2,037  16    Provider Technologies Software & software systems 111  104  7  374  322  16  Services 435  287  52  1,365  1,069  28  Hardware   51    40  28    166    151  10  Total Provider Technologies   597    431  39    1,905    1,542  24  Revenues $ 24,165  $ 22,790  6  $ 92,977  $ 86,983  7    GROSS PROFIT Pharmaceutical Solutions $ 794  $ 684  16  $ 2,757  $ 2,485  11  Medical-Surgical Solutions 171  147  16  676  572  18  Provider Technologies   286    208  38    899    720  25  Gross profit $ 1,251  $ 1,039  20  $ 4,332  $ 3,777  15    OPERATING EXPENSES Pharmaceutical Solutions $ 395  $ 344  15  $ 1,434  $ 1,311  9  Medical-Surgical Solutions 160  132  21  597  492  21  Provider Technologies 237  164  45  749  590  27  Corporate   91    69  32    294    213  38  Subtotal 883  709  25  3,074  2,606  18  Securities Litigation charge (credit), net   -    (8) -    (6)   45  -  Operating expenses $ 883  $ 701  26  $ 3,068  $ 2,651  16    OTHER INCOME, NET Pharmaceutical Solutions $ 8  $ 12  (33) $ 38  $ 37  3  Medical-Surgical Solutions -  1  -  2  3  (33) Provider Technologies 2  4  (50) 9  13  (31) Corporate   16    25  (36)   83    86  (3) Other income, net $ 26  $ 42  (38) $ 132  $ 139  (5)   OPERATING PROFIT Pharmaceutical Solutions $ 407  $ 352  16  $ 1,361  $ 1,211  12  Medical-Surgical Solutions 11  16  (31) 81  83  (2) Provider Technologies   51    48  6    159    143  11  Operating profit 469  416  13  1,601  1,437  11  Corporate (75) (44) 70  (211) (127) 66  Securities Litigation (charge) credit, net   -    8  -    6    (45) -  Income from continuing operations before interest expense and income taxes $ 394  $ 380  4  $ 1,396  $ 1,265  10    Operating profit as a % of revenues Pharmaceutical Solutions 1.77% 1.61% 16  bp 1.53% 1.45% 8  bp Medical-Surgical Solutions 1.91% 3.15% (124) 3.43% 4.07% (64) Provider Technologies 8.54% 11.14% (260) 8.35% 9.27% (92)   Return on Stockholders' Equity (1) 15.2% 13.1%   (1) Ratio is computed as the sum of net income for the last four quarters, divided by the average of stockholders' equity for the last five quarters. Ratio includes our after-tax Securities Litigation charges and credits. Schedule III McKESSON CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions)   March 31, March 31, 2007  2006    ASSETS Current Assets Cash and cash equivalents $ 1,954  $ 2,139  Restricted cash 984  962  Receivables, net 6,566  6,247  Inventories 8,153  7,127  Prepaid expenses and other   199    522  Total 17,856  16,997  Property, Plant and Equipment, net 684  663  Capitalized Software Held for Sale 166  139  Goodwill 2,975  1,637  Other Intangibles 613  116  Other Assets   1,649    1,409  Total Assets $ 23,943  $ 20,961    LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Drafts and accounts payable $ 10,873  $ 9,944  Deferred revenue 1,027  827  Current portion of long-term debt 155  26  Securities Litigation 983  1,014  Other   2,088    1,659  Total 15,126  13,470  Postretirement Obligations and Other Noncurrent Liabilities 741  619  Long-Term Debt 1,803  965  Stockholders' Equity   6,273    5,907  Total Liabilities and Stockholders' Equity $ 23,943  $ 20,961  Schedule IV McKESSON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in millions)   Year Ended March 31, FY07 FY06   OPERATING ACTIVITIES Net income $ 913  $ 751  Discontinued operations, net of income taxes 55  (6) Adjustments to reconcile to net cash provided by operating activities: Depreciation and amortization 295  262  Securities Litigation charge (credit), net (6) 45  Deferred taxes 167  403  Other non-cash items (52) (37) Changes in operating assets and liabilities, net of business acquisitions: Receivables (209) (519) Inventories (928) 601  Drafts and accounts payable 872  1,104  Deferred revenue 181  379  Taxes 144  (53) Securities Litigation settlement payments (25) (243) Other   132    51  Net cash provided by operating activities   1,539    2,738    INVESTING ACTIVITIES Property acquisitions (126) (166) Capitalized software expenditures (180) (160) Acquisitions of businesses, less cash and cash equivalents acquired (1,938) (589) Proceeds from sales of businesses 179  63  Restricted cash (22) (962) Other   (16)   (2) Net cash used in investing activities   (2,103)   (1,816)   FINANCING ACTIVITIES Proceeds from issuances of debt, net 1,997  -  Repayment of debt (1,031) (24) Capital stock transactions: Issuances 399  568  Share repurchases (1,003) (958) ESOP notes and guarantees 10  12  Dividends paid (72) (73) Other   79    (108) Net cash provided by (used in) financing activities   379    (583)   Net increase (decrease) in cash and cash equivalents (185) 339  Cash and cash equivalents at beginning of period   2,139    1,800  Cash and cash equivalents at end of period $ 1,954  $ 2,139